Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Staffurth

Showing results (61-70 of 84) with videos related to

Pageof 9
Sort By:
International Journal of Radiation Oncology, Biology, Physics|May 4, 2018
The Efficacy and Safety of Conventional and Hypofractionated High-Dose Radiation Therapy for Prostate Cancer in an Elderly Population: A Subgroup Analysis of the CHHiP TrialJames M Wilson, David P Dearnaley, Isabel Syndikus, et al.
The Lancet. Oncology|November 3, 2015
Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trialAnna Wilkins, Helen Mossop, Isabel Syndikus, et al.
JAMA Oncology|January 23, 2016
Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both: The TRAPEZE Randomized Clinical TrialNicholas D James, Sarah J Pirrie, Ann M Pope, et al.
International Journal of Radiation Oncology, Biology, Physics|December 14, 2020
Clinical Outcomes of a Randomized Trial of Adaptive Plan-of-the-Day Treatment in Patients Receiving Ultra-hypofractionated Weekly Radiation Therapy for Bladder CancerRobert Huddart, Shaista Hafeez, Rebecca Lewis, et al.
BJU International|June 4, 2016
Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747)Lazaros Andronis, Ilias Goranitis, Sarah Pirrie, et al.
The Lancet. Oncology|June 15, 2025
Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trialAlison C Tree, Victoria Hinder, Andrew Chan, et al.
The New England Journal of Medicine|October 16, 2024
Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate CancerNicholas van As, Clare Griffin, Alison Tree, et al.
The New England Journal of Medicine|September 15, 2016
10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate CancerFreddie C Hamdy, Jenny L Donovan, J Athene Lane, et al.
BJU International|January 5, 2020
The ProtecT trial: analysis of the patient cohort, baseline risk stratification and disease progressionRichard J Bryant, Jon Oxley, Grace J Young, et al.
The Lancet. Oncology|June 25, 2016
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trialDavid Dearnaley, Isabel Syndikus, Helen Mossop, et al.
Pageof 9

Showing results (61-70 of 84) with videos related to

Sort By:
Pageof 9
International Journal of Radiation Oncology, Biology, Physics|May 4, 2018
The Efficacy and Safety of Conventional and Hypofractionated High-Dose Radiation Therapy for Prostate Cancer in an Elderly Population: A Subgroup Analysis of the CHHiP TrialJames M Wilson, David P Dearnaley, Isabel Syndikus, et al.
The Lancet. Oncology|November 3, 2015
Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trialAnna Wilkins, Helen Mossop, Isabel Syndikus, et al.
JAMA Oncology|January 23, 2016
Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both: The TRAPEZE Randomized Clinical TrialNicholas D James, Sarah J Pirrie, Ann M Pope, et al.
International Journal of Radiation Oncology, Biology, Physics|December 14, 2020
Clinical Outcomes of a Randomized Trial of Adaptive Plan-of-the-Day Treatment in Patients Receiving Ultra-hypofractionated Weekly Radiation Therapy for Bladder CancerRobert Huddart, Shaista Hafeez, Rebecca Lewis, et al.
BJU International|June 4, 2016
Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747)Lazaros Andronis, Ilias Goranitis, Sarah Pirrie, et al.
The Lancet. Oncology|June 15, 2025
Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trialAlison C Tree, Victoria Hinder, Andrew Chan, et al.
The New England Journal of Medicine|October 16, 2024
Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate CancerNicholas van As, Clare Griffin, Alison Tree, et al.
The New England Journal of Medicine|September 15, 2016
10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate CancerFreddie C Hamdy, Jenny L Donovan, J Athene Lane, et al.
BJU International|January 5, 2020
The ProtecT trial: analysis of the patient cohort, baseline risk stratification and disease progressionRichard J Bryant, Jon Oxley, Grace J Young, et al.
The Lancet. Oncology|June 25, 2016
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trialDavid Dearnaley, Isabel Syndikus, Helen Mossop, et al.
Pageof 9